Information de reference pour ce titreAccession Number: | 00006534-200804000-00010.
|
Author: | Wong, Alex K. M.D.; Schonmeyer, Bjorn H. M.D.; Singh, Paramjeet M.D.; Carlson, Diane L. M.D.; Li, Sen M.S.; Mehrara, Babak J. M.D.
|
Institution: | New York, N.Y. From the Plastic and Reconstructive Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center.
|
Title: | |
Source: | Plastic & Reconstructive Surgery. 121(4):1144-1152, April 2008.
|
Abstract: | Background: Acellular dermal matrix (AlloDerm) is used frequently in a variety of reconstructive procedures. Although it is clear that AlloDerm is revascularized by host tissues, the mechanisms by which vascularization and tissue incorporation occur remain essentially unknown. The purpose of this experiment was to delineate the time course and composition of host cell infiltrate into the matrix of an AlloDerm composite flap.
Methods: A flap based on the superficial inferior epigastric pedicle in the rat was developed and used to obtain tissue specimens at 3, 7, and 14 days after implantation of AlloDerm. Histology, bromodeoxyuridine incorporation, and immunohistologic assays were used to temporally characterize the appearance of myofibroblasts, endothelial cells, and lymphatic endothelial cells within the matrix.
Results: Active host cell proliferation occurs within the matrix at 7 days after implantation. The total number of both host cells and myofibroblasts increased by 8-fold between days 3 and 14. There was a 4-fold increase in endothelial cells between days 3 and 7 but no significant increase at day 14. Putative lymphatic channels were identified within the matrix by 14 days and confirmed using immunohistochemistry for Prox-1, a well-established lymphatic endothelial cell marker.
Conclusions: The host response to AlloDerm parallels normal wound healing. Host cell infiltrate increases steadily over a 14-day period. By 7 days after implantation, a large number of CD31+ endothelial cells have infiltrated the matrix and early vessels are abundantly present. These vessels continue to mature by day 14. Finally, the authors show that AlloDerm composite flaps also support infiltration and development of a lymphatic network.
(C)2008American Society of Plastic Surgeons
|
References: | 1. Menon, N. G., Rodriguez, E. D., Byrnes, C. K., Girotto, J. A., Goldberg, N. H., and Silverman, R. P. Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model. Ann. Plast. Surg. 50: 523, 2003.
2. Buinewicz, B., and Rosen, B. Acellular cadaveric dermis (AlloDerm): A new alternative for abdominal hernia repair. Ann. Plast. Surg. 52: 188, 2004.
3. Kolker, A. R., Brown, D. J., Redstone, J. S., Scarpinato, V. M., and Wallack, M. K. Multilayer reconstruction of abdominal wall defects with acellular dermal allograft (AlloDerm) and component separation. Ann. Plast. Surg. 55: 36, 2005.
4. Butler, C. E., Langstein, H. N., and Kronowitz, S. J. Pelvic, abdominal, and chest wall reconstruction with AlloDerm in patients at increased risk for mesh-related complications. Plast. Reconstr. Surg. 116: 1263, 2005.
5. Glasberg, S. B., and D'Amico, R. A. Use of regenerative human acellular tissue (AlloDerm) to reconstruct the abdominal wall following pedicle TRAM flap breast reconstruction surgery. Plast. Reconstr. Surg. 118: 8, 2006.
6. Weber, P. C., Lambert, P. R., Cunningham, C. D., III, Richardson, M. S., and Genao, R. B. Use of Alloderm in the neurotologic setting. Am. J. Otolaryngol. 23: 148, 2002.
7. Lorenz, R. R., Dean, R. L., Hurley, D. B., Chuang, J., and Citardi, M. J. Endoscopic reconstruction of anterior and middle cranial fossa defects using acellular dermal allograft. Laryngoscope 113: 496, 2003.
8. Taban, M., Douglas, R., Li, T., Goldberg, R. A., and Shorr, N. Efficacy of "thick" acellular human dermis (AlloDerm) for lower eyelid reconstruction: Comparison with hard palate and thin AlloDerm grafts. Arch. Facial Plast. Surg. 7: 38, 2005.
9. Livesey, S. A., Herndon, D. N., Hollyoak, M. A., Atkinson, Y. H., and Nag, A. Transplanted acellular allograft dermal matrix: Potential as a template for the reconstruction of viable dermis. Transplantation 60: 1, 1995.
10. Dubin, M. G., Feldman, M., Ibrahim, H. Z., et al. Allograft dermal implant (AlloDerm) in a previously irradiated field. Laryngoscope 110: 934, 2000.
11. Sclafani, A. P., Romo, T., III, Jacono, A. A., McCormick, S., Cocker, R., and Parker, A. Evaluation of acellular dermal graft in sheet (AlloDerm) and injectable (micronized AlloDerm) forms for soft tissue augmentation: Clinical observations and histological analysis. Arch. Facial Plast. Surg. 2: 130, 2000.
12. Sclafani, A. P., McCormick, S. A., and Cocker, R. Biophysical and microscopic analysis of homologous dermal and fascial materials for facial aesthetic and reconstructive uses. Arch. Facial Plast. Surg. 4: 164, 2002.
13. Butler, C. E., and Prieto, V. G. Reduction of adhesions with composite AlloDerm/polypropylene mesh implants for abdominal wall reconstruction. Plast. Reconstr. Surg. 114: 464, 2004.
14. Silverman, R. P., Li, E. N., Holton, L. H., III, Sawan, K. T., and Goldberg, N. H. Ventral hernia repair using allogenic acellular dermal matrix in a swine model. Hernia 8: 336, 2004.
15. Ophof, R., Maltha, J. C., Von den Hoff, J. W., and Kuijpers-Jagtman, A. M. Histologic evaluation of skin-derived and collagen-based substrates implanted in palatal wounds. Wound Repair Regen. 12: 528, 2004.
16. Chung, S., Hazen, A., Levine, J. P., et al. Vascularized acellular dermal matrix island flaps for the repair of abdominal muscle defects. Plast. Reconstr. Surg. 111: 225, 2003.
17. Desmouliere, A., Chaponnier, C., and Gabbiani, G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 13: 7, 2005.
18. Darby, I., Skalli, O., and Gabbiani, G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab. Invest. 63: 21, 1990.
19. Newman, P. J., Berndt, M. C., Gorski, J., et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247: 1219, 1990.
20. Wigle, J. T., and Oliver, G. Prox1 function is required for the development of the murine lymphatic system. Cell 98: 769, 1999.
21. Wigle, J. T., Harvey, N., Detmar, M., et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. E.M.B.O. J. 21: 1505, 2002.
22. Wilting, J., Papoutsi, M., Christ, B., et al. The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. F.A.S.E.B. J. 16: 1271, 2002.
23. Hong, Y. K., Harvey, N., Noh, Y. H., et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev. Dyn. 225: 351, 2002.
24. Slavin, S. A., Van den Abbeele, A. D., Losken, A., Swartz, M. A., and Jain, R. K. Return of lymphatic function after flap transfer for acute lymphedema. Ann. Surg. 229: 421, 1999.
|
Language: | English.
|
Document Type: | EXPERIMENTAL: ORIGINAL ARTICLES.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0032-1052
|
NLM Journal Code: | 1306050, p9s
|
DOI Number: | https://dx.doi.org/10.1097/01.pr...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|